CN119173507A - 2-甲基-2-噻唑啉的盐 - Google Patents

2-甲基-2-噻唑啉的盐 Download PDF

Info

Publication number
CN119173507A
CN119173507A CN202380039183.5A CN202380039183A CN119173507A CN 119173507 A CN119173507 A CN 119173507A CN 202380039183 A CN202380039183 A CN 202380039183A CN 119173507 A CN119173507 A CN 119173507A
Authority
CN
China
Prior art keywords
salt
methyl
thiazoline
deuterated
ndsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380039183.5A
Other languages
English (en)
Chinese (zh)
Inventor
谷川清
丸桥和夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myrodia Therapy Co ltd
Original Assignee
Myrodia Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myrodia Therapy Co ltd filed Critical Myrodia Therapy Co ltd
Publication of CN119173507A publication Critical patent/CN119173507A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380039183.5A 2022-05-10 2023-05-10 2-甲基-2-噻唑啉的盐 Pending CN119173507A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-077593 2022-05-10
JP2022077593 2022-05-10
PCT/JP2023/017574 WO2023219106A1 (ja) 2022-05-10 2023-05-10 ２－メチル－２－チアゾリンの塩

Publications (1)

Publication Number Publication Date
CN119173507A true CN119173507A (zh) 2024-12-20

Family

ID=88730312

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380039183.5A Pending CN119173507A (zh) 2022-05-10 2023-05-10 2-甲基-2-噻唑啉的盐

Country Status (5)

Country Link
US (1) US20250304540A1 (https=)
EP (1) EP4524132A4 (https=)
JP (1) JPWO2023219106A1 (https=)
CN (1) CN119173507A (https=)
WO (1) WO2023219106A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785373A (en) * 1953-12-23 1957-10-30 Organon Labor Ltd Process for the preparation of heterocyclic compounds
GB1170841A (en) * 1967-02-09 1969-11-19 Bellon Labor Sa Roger Substituted delta<2>-Thiazolines and their preparation
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
KR20110022611A (ko) * 2008-06-20 2011-03-07 아스트라제네카 아베 베타２－아드레날린수용체 활성의 조절을 위한, ４－히드록시－２－옥소－２,３－디히드로－１,３－벤조티아졸－７－일 화합물을 포함하는 제약 조성물
TW201106101A (en) * 2009-06-01 2011-02-16 Fujifilm Electronic Materials Chemically amplified positive photoresist composition
CN112105616B (zh) * 2018-02-02 2023-09-01 基因技术公司 药学化合物、其盐类、其制剂和其制备和使用方法
JP7321534B2 (ja) * 2018-03-16 2023-08-07 脳科学香料株式会社 低酸素障害、虚血再灌流障害又は炎症の予防又は治療剤、移植用細胞保護剤、及び生体保存剤
JP7491815B2 (ja) 2020-11-12 2024-05-28 ルネサスエレクトロニクス株式会社 半導体装置の製造方法

Also Published As

Publication number Publication date
EP4524132A1 (en) 2025-03-19
US20250304540A1 (en) 2025-10-02
JPWO2023219106A1 (https=) 2023-11-16
WO2023219106A1 (ja) 2023-11-16
EP4524132A4 (en) 2026-04-22

Similar Documents

Publication Publication Date Title
JP7627974B2 (ja) Ｃｄｋ７キナーゼ阻害剤として使用される化合物およびその適用
EP3473626B1 (en) Pyrrolopyrimidine crystal for preparing jak inhibitor
AU2017380213B2 (en) Crystalline forms of a janus kinase inhibitor
US20250163055A1 (en) Polymorph of jak tyrosine kinase inhibitor and preparation method therefor
EP4650351A1 (en) Inhibitor of complement factor b
US11124517B2 (en) Crystal form of Baricitinib and preparation method thereof
TWI870440B (zh) 活化素受體樣激酶抑制劑之鹽及晶體形式
US20250011337A1 (en) Crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them
WO2025093059A1 (zh) 3-(氨基)亚甲基吲哚啉类衍生物及其制备方法和应用
TW202124373A (zh) 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法
WO2025093060A1 (zh) 3-(吲哚氨基)亚甲基吲哚啉类衍生物及其制备方法和应用
CN108299263B (zh) 一种普罗布考衍生物及其制备方法与应用
JP2024517608A (ja) 結晶性カルバゾール誘導体
CN119173507A (zh) 2-甲基-2-噻唑啉的盐
WO2025093058A1 (zh) 2-氧代吲哚啉类衍生物及其制备方法和应用
US11299462B2 (en) Crystal form of oxopicolinamide derivative and preparation method therefor
EP4144742A1 (en) Inositol derivative and use thereof
US9409857B2 (en) Agomelatine sulfuric acid complex, and preparation method and application thereof
CN118108704A (zh) Kif18a抑制剂
CA3246202A1 (en) CRYSTALLINE FORMS AND SALTS OF A PI3K INHIBITOR AND THEIR PROCESSES OF MANUFACTURE AND USE
AU2023236233A1 (en) Salt form and crystal form of vanin enzyme inhibitor, method for preparing same, and use thereof
US20240368088A1 (en) Ep4 antagonist compound as well as salt, polymorph and use thereof
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
WO2022048620A1 (en) Polymorphs of crystalline forms of 3, 10-dimethoxy-5, 8, 13, 13a-tetrahydro-6h-isoquinolino [3, 2-a] isoquinolin-9-yl 3-fluorobenzenesulfonate and salts thereof
EP4703363A1 (en) Salt form and crystal form of thienopyrimidine compound, and preparation method therefor and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination